BIO-TECHNE Corp
TECH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TECH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TECH
Bio-Techne Corp is a life sciences tools company providing reagents, assays, and diagnostics for research and clinical markets, with a focus on protein sciences and spatial biology.
Key risk: Flat organic revenue growth
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 27 clinical trials · 8 catalysts for BIO-TECHNE Corp.
Bio-Techne Corp is a life sciences tools company providing reagents, assays, and diagnostics for research and clinical markets, with a focus on protein sciences and spatial biology.
- Fiscal 2026 net sales were flat at $1.2 billion compared to fiscal 2025 [sec_mda · as of 2026-08-24].
- Adjusted operating margin for fiscal 2025 was 31.6% with adjusted EPS of $1.92 [sec · filed 2025-09-19].
- Cash and equivalents were $264.7M as of 2026-06-30, with shareholders' equity of $1,918.8M and total debt of $200.0M [latest reported financials].
- The company completed the acquisition of Lunaphore in fiscal 2024 for $169.7 million [sec_mda · as of 2025-08-22].
- A merger is expected to close by late 2026 or early 2027, subject to regulatory approvals [sec_mda · as of 2026-08-24].
What works
- Strong cash generation from operations: $196.7M in the nine months ended March 31, 2026 [sec · filed 2026-05-06].
- High adjusted operating margin of 31.6% in fiscal 2025 demonstrates profitability focus [sec · filed 2025-09-19].
- Strategic acquisitions like Lunaphore ($169.7M) and planned acquisition of Wilson Wolf support growth in spatial biology and cell analysis [sec_mda · as of 2025-08-22].
- Solid balance sheet with $264.7M cash and $800M undrawn credit facility provides liquidity for operations and expansion [sec_mda · as of 2026-08-24].
What to weigh
- Fiscal 2026 net sales remained flat year-over-year, indicating stalled organic growth [sec_mda · as of 2026-08-24].
- GAAP EPS was only $0.46 in fiscal 2025, significantly lower than adjusted EPS of $1.92, suggesting large non-cash charges [sec · filed 2025-09-19].
- Cash from operations decreased to $110.0M in H1 fiscal 2026 from $148.2M in the prior-year period, partly due to timing of payments [sec_mda · as of 2026-02-04].
- The merger closing is subject to regulatory approvals and may face delays or burdensome conditions [sec_mda · as of 2026-08-24].
From the filings
Quoted directly from source documents.
Fiscal 2026 net sales were flat at $1.2 billion
“For fiscal 2026, consolidated net sales remained flat at $1.2 billion as compared to fiscal 2025.”
SEC MD&A · August 24, 2026
Adjusted operating margin of 31.6% in fiscal 2025
“achieving an adjusted operating margin of 31.6% for the year.”
SEC filings · September 19, 2025
Cash from operations of $196.7M in nine months ended March 31, 2026
“The Company generated cash of $196.7 million from operating activities in the nine months ended March 31, 2026”
SEC filings · May 6, 2026
Merger expected to close by late 2026 or early 2027
“The Merger is expected to close by late 2026 or early 2027.”
SEC MD&A · August 24, 2026
Catalyst timeline
- 2026-12-25 · Phase3_Topline — Topline data from a randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and safety of an undisclosed therapy.
- 2027-02-01 · Phase3_Topline — Topline data from a multicenter, randomized, double-blind, placebo-controlled Phase III study.
- 2028-09-01 · Phase3_Topline — Topline data from a Phase II/III randomized, double-blind, placebo-controlled, multi-center study.
- 2029-04-01 · Phase3_Topline · non-segmental — Topline data from a Phase II/III adaptive design study for a non-segmental indication.
- 2030-02-25 · Phase3_Topline — Topline data from a randomized, controlled, open-label Phase III clinical trial.
- 2030-05-31 · Phase3_Topline · dalpiciclib — Topline data from a randomised, open-label, multicentre Phase III study evaluating dalpiciclib.
- 2031-07-25 · Phase3_Topline · icp-248 — Topline data from a Phase II/III study of ICP-248 in combination with orelabrutinib in treatment-naïve CLL.
- 2033-12-01 · Phase3_Topline · orelabrutinib — Topline data from a randomized, multicenter, open-label Phase III study comparing ICP-248 plus orelabrutinib.
Risks & what to watch (4)›
Key risks
- Flat organic revenue growth — Fiscal 2026 net sales were flat at $1.2B, indicating stalled organic growth [sec_mda · as of 2026-08-24].
- Merger regulatory approval risk — Merger closing subject to regulatory approvals without burdensome conditions, may be delayed [sec_mda · as of 2026-08-24].
- Declining operating cash flow — Operating cash flow fell to $110M in H1 fiscal 2026 from $148.2M a year earlier [sec_mda · as of 2026-02-04].
- Large GAAP vs adjusted EPS gap — GAAP EPS of $0.46 vs adjusted $1.92 in fiscal 2025 implies significant non-cash charges [sec · filed 2025-09-19].
What to watch
- Merger closing timeline and any regulatory conditions [sec_mda · as of 2026-08-24].
- Organic revenue growth trajectory in upcoming quarters [sec_mda · as of 2026-08-24].
- Integration and revenue contribution from Lunaphore and Wilson Wolf acquisitions [sec_mda · as of 2025-08-22].
- Cash flow trends and ability to maintain dividends and capital spending [sec · filed 2026-05-06].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BIO-TECHNE Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIO-TECHNE Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.23
No tracked pipeline phase
No tracked pipeline candidates
8 upcoming, next in ~117d
0 buys · 1 sell (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
580
Total value held
$9.37B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 20,359,418 | $1.06B |
| blackrock, inc. | 12,264,513 | $640.9M |
| morgan stanley | 8,532,873 | $445.9M |
| fmr llc | 7,899,928 | $412.9M |
| vanguard portfolio management llc | 6,480,337 | $338.7M |
| state street corp | 5,868,396 | $306.7M |
| wellington management group llp | 5,120,185 | $267.6M |
| geode capital management, llc | 5,112,420 | $266.8M |
| maverick capital ltd | 4,739,721 | $247.7M |
| durable capital partners lp | 4,456,017 | $232.9M |
Showing top 10 of 580 institutional holders of BIO-TECHNE Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.7%
- Days to cover
- 6.6
- Shares short
- 13,338,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TECH short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIO-TECHNE Corp?
Bio-Techne Corp is a life sciences tools company providing reagents, assays, and diagnostics for research and clinical markets, with a focus on protein sciences and spatial biology.
What is BIO-TECHNE Corp's next catalyst?
BIO-TECHNE Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of" — expected December 25, 2026.
Who is the CEO of BIO-TECHNE Corp?
Mr. Kim Kelderman is the chief executive officer of BIO-TECHNE Corp (TECH).
Where is BIO-TECHNE Corp headquartered?
BIO-TECHNE Corp (TECH) is headquartered in Minneapolis, MN, United States.
What therapeutic areas does BIO-TECHNE Corp focus on?
BIO-TECHNE Corp develops therapies across Oncology, Neurology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.